Reviewer’s report
Title: 
CCDC114, DNAI2 and TOP2A  involves in the effects of Tibolone
treatment on postmenopausal endometrium
Version: 
0 
Date: 
16 Jan 2020
Reviewer: 
Hassan Abduljabbar
Reviewer's report:
Please include all comments for the authors in this box rather than uploading
your report as an attachment. Please only upload as attachments annotated
versions of manuscripts, graphs, supporting materials or other aspects of your
report which cannot be included in a text format.
Please overwrite this text when adding your comments to the authors.
BMC Women's Health
Potential molecular mechanism investigation of Tibolone treatment for
postmenopausal
Women
Manuscript Number: BMWH-D-19-00839
Generally 
The title; (Potential molecular mechanism investigation of Tibolone treatment
for postmenopausal women)
a. The title reflect the study 
b. It involves an important area gynecology 
c. (Not Original) 
Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical
recommendations for the use of tibolone in Asian women. Climacteric. 2010
Aug;13(4):317-27. doi: 10.3109/13697131003681458. Review.
Notelovitz M. Postmenopausal tibolone therapy: biologic principles and applied
clinical practice. MedGenMed. 2007 Jan 3;9(1):2. Review. PMID: 17435612
d. There is an important massage 
e. Has additional knowledge to the medical literature. 
The abstract of manuscript very well written. 
1. It is a good summary and
2. The Aim is clear (aimed to explore the molecular mechanism of Tibolone in
postmenopausal women.)
3. Background: 
* Induced abortion in sub-Saharan Africa is an underreported and unrevealed
health problem. 
* Often it is done in a setting where there are minimum medical standards and
by personnel with skill gaps.
Methods 
Gene expression profile GSE12446 including 9 human endometrial samples from
postmenopausal women treated with Tibolone (Tibolone group) and 
9 control samples (control group) was downloaded. 
The differentially expressed genes (DEGs) were investigated, followed by
function and pathway enrichment on these DEGs.
Then the protein-protein interaction network (PPI) and modules analysis were
performed. 
Finally, the drug-target interaction and novel drugs prediction were performed
based on DEGs obtained in this study.
Results 
A total of 238 up-regulated DEGs and 72 down-regulated DEGs were
investigated. 
These DEGs were mainly assembled in functions like cilium movement and
pathways like systemic lupus erythematosus (SLE). 
Moreover, a total of 20 outstanding genes including up-regulated Coiled-Coil
Domain Containing (CCDC) 114 and Dynein Axonemal Intermediate Chain
(DNAI) 2 were revealed in PPI network.
Furthermore, a total of 8 genes (such as DNA Topoisomerase II A (TOP2A))
and 94 drugs (such as Epirubicin) 
were explored using drug-gene interaction analysis.
Discussion 
Most discussion is a repeat of results 
Short and need to be rewritten and 
Should contain more study in the same points 
Need more details information about the subject .
Conclusion
The up-regulated CCDC114 and DNAI2 might play important roles in Tibolone-
treated postmenopausal women via cilium movement function. 
Moreover, Tibolone might affect the regulation of SLE pathway in
postmenopausal women. 
TOP2A might be a breakthrough for novel drugs investigation for
postmenopausal women. 
The manuscript 
It is a well written in (English language with few spelling and grammar
mistakes.)
Important points of the subject 
with few information and knowledge about the subject 
The length of the text is appropriate. 
Although Discussion is short 
The Figure are clear (need more explanation)
Statistical analysis is basic but appropriate. 
Discussion is short but clear and need to contain more details information about
the subject 
Plagiarism 
(some text taken from the web )
No conflicts of interests.
References (total 44 few references are old before 2009 ) 

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the
authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you
recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects
require further assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
'I declare that I have no competing interests'
I agree to the open peer review policy of the journal. I understand that my name
will be included on my report to the authors and, if the manuscript is accepted
for publication, my named report including any attachments I upload will be
posted on the website along with the authors' responses. I agree for my report to
be made available under an Open Access Creative Commons CC-BY license
(
http://creativecommons.org/licenses/by/4.0/
). I understand that any comments
which I do not wish to be included in my named report can be included as
confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal